# Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

> **NCT00974792** · PHASE2 · UNKNOWN · sponsor: **Cancer Research UK** · enrollment: 150 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide phosphate
- **DRUG:** ifosfamide
- **DRUG:** leucovorin calcium
- **DRUG:** methotrexate
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00974792
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-01
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00974792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00974792, "Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00974792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*